In a tender offer, shareholders sell to outside investors with no fresh capital raised and no financials released, so ElevenLabs' $22B is a second hand share price, not a disclosed valuation.
For the third time in less than two years, ElevenLabs is letting outside investors set a price on its existing shares.
ElevenLabs is in early discussions with investors about a tender offer that would value the voice AI startup at roughly $22 billion, almost double the $11 billion mark set during its Series D in February. Bloomberg reported the talks on July 2; terms are still preliminary and could change, and the company declined to comment on the discussions.
A tender offer, especially a secondary one, is not a funding round. Existing shareholders sell pieces of their stake to outside investors, while the company itself receives no new cash, issues no new stock, and files no prospectus. That makes the $22 billion figure a price on second-hand shares rather than a public valuation backed by audited revenue, retention, or growth metrics. Coverage from The Next Web and other pickup outlets has tracked the wire since Bloomberg's initial report.
Three upward re-pricings have set the run-up. ElevenLabs' February Series D publicly landed at about $11 billion. Two earlier tenders had already pushed the mark upward, each iteration faster than the last. A $22 billion target now, roughly double the Series D and reached in less than five months, would mark a third re-pricing in under two years. All three have worked through mechanisms that reward early employees and investors without putting fresh capital on ElevenLabs' balance sheet.
Without a primary raise, ElevenLabs owes the public no audited revenue, no ARR multiple, no forward growth guidance. Outsiders buying second-hand shares agree to a private price set largely by negotiation, often anchored to whatever the most recent comparable deal traded at. Each successful tender at a higher mark narrows the discount future buyers will accept. The falsifier for the pattern is easy to name: an S-1 filing, an IPO, or a primary capital raise that brings in outside cash and forces real metrics into the open. Until then, $22 billion is a market-maker's view of a stock that has no public float and no prospectus.
ElevenLabs, a voice cloning and voice AI platform, originated from a founder's frustration with dubbed films and has been described in pickup coverage as one of the fastest-growing software companies in Europe. The company blog carries product announcements but, like the rest of its public footprint, contains no audited growth figures.
The expected close is September 2026 if the terms hold. Watch whether the deal clears at $22 billion, lands lower, or stalls entirely. Watch harder for what comes next: a primary round, an S-1, or any disclosure that breaks the pattern this tender is built to preserve. A public filing would force ElevenLabs to defend a $22 billion number with revenue, retention, or growth metrics that the secondary market has so far been allowed to assume.